Saturday, February 11, 2017 9:05:46 AM
Listen, I respect your position. I still believe in the treatment, that is why I still hold shares, but I am concerned that the next round of financing will be for CAN .10 w/warrants and I just think the CEO talking about THAT would be nice.
Anyone that knows anything about clinical trials should have already known the info in the interview - as they said, if you didn't you shouldn't be investing on your own. How about giving us some info we don't know - like where future funding is going to come from? I don't see things progressing quickly enough not to need another cash infusion or two...or three....before we get to partnership talk.
I could be wrong, I hope I am - but I think for everyone on this board THAT would be a much more valuable conversation than what the interview dealt with --- '
Following the charts is like driving a car forward while looking in the rear view mirror.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM